The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KYMR | +156.58% | +73.29% | +11.61% | +151% |
| S&P | +17.45% | +75.43% | +11.88% | +98% |
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
Kymera Therapeutics develops targeted protein degradation therapies for immunology, oncology, and fibrosis using proprietary technology.
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.87M | -61.2% |
| Gross Profit | $838.00K | -84.5% |
| Gross Margin | 29.20% | -44.1% |
| Market Cap | $6.14B | 135.8% |
| Market Cap / Employee | $25.81M | 79.3% |
| Employees | 238 | 26.6% |
| Net Income | -$86,981.00K | -22.9% |
| EBITDA | -$95,864.00K | -21.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $357.01M | 196.9% |
| Accounts Receivable | $0.00K | -100.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $68.50M | -8.2% |
| Short Term Debt | $13.76M | 4.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -22.89% | 5.9% |
| Return On Invested Capital | -24.56% | 10.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$66,853.00K | -6.6% |
| Operating Free Cash Flow | -$66,747.00K | -8.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.13 | 3.61 | 4.11 | 5.90 | 102.22% |
| Price to Sales | 37.25 | 78.52 | 112.98 | 178.43 | 161.01% |
| Price to Tangible Book Value | 2.13 | 3.61 | 4.11 | 5.90 | 102.22% |
| Enterprise Value to EBITDA | -25.10 | -35.54 | -52.24 | -64.99 | 81.76% |
| Return on Equity | -32.2% | -33.3% | -32.1% | -25.8% | -29.14% |
| Total Debt | $86.33M | $85.71M | $84.00M | $82.25M | -6.28% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
